Investor Presentation First Nine Months of 2022
120
Investor presentation First nine months of 2022
Region China at a glance.
Region China
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
First nine months of Sales
2022
Growth²
(mDKK)
200
30
100%
6%
Total GLP-13
2,737
87%
14%
160
25
25
GLP-1
80%
Long-acting insulin4
1,329
-23%
82.5%1
20
120
20
Premix insulin5
3,913
-12%
60%
Fast-acting insulin
1,583
-19%
Insulin
15
Human insulin
175
1,480
-36%
80
164
12.2%1
40%
141
10
Total insulin
8,305
-21%
40
40
Other Diabetes care?
960
-24%
20%
5
9.4%1
OAD
Diabetes care
12,002
-9%
0
2021
0
0%
Obesity care
110
168%
Aug
2030
2045
2017
Population with diabetes
Diabetes growth rate
-GLP-1 MS
-Insulin MS
Aug
2022
-OAD MS
Diabetes & Obesity care
12,112
-9%
Rare disease8
733
131%
Total
12,845
-5%
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
Region China covers Mainland China, Taiwan, and Hong Kong
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Aug 2022: Novo Nordisk 50%, Sanofi 17%,
Gan & Lee 13% and Eli Lilly 8%; Competitor GLP-1 value market shares, as of Aug 2022:
Novo Nordisk 67% and Eli Lilly 25%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Aug 2022 value figures
4
2 At constant exchange rates; 3 Comprises VictozaⓇ and OzempicⓇ;
Comprises Tresiba, XultophyⓇ and LevemirⓇ; 5 Comprises NovoMix® and
Ryzodeg®: 6 Comprises NovoRapid®; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ; 9 Comprises primarily NovoSeven®, Novo Eight® and
NorditropinⓇView entire presentation